InvestorsHub Logo
Followers 84
Posts 1928
Boards Moderated 0
Alias Born 03/05/2014

Re: None

Thursday, 01/23/2020 1:39:09 PM

Thursday, January 23, 2020 1:39:09 PM

Post# of 232286
As many know I am very critical of Nader’s presentation skills. IMHO I thought he did a good job with the presentation and an even better job of answering questions.

His explanation of the delays that have occurred with the submission of the BLA was turned into a positive. The additional demands that the FDA made have provided a better platform for Leronlimab.

BLA submission is still on schedule for end of January. Could slip a week or two but they are all over the final details working around the clock.

His explanation of the MOA and impact on Macrophages was powerful. He explains in layman terms what separates Leronlimab from Maravirov and other CCR5 inhibitors.

Patients 3 and 4 have been injected - #3 was Jan. 2 and he expects first data on these patients as early as next week. He also expects patients 5,6,and 7 to be injected by end of next week. He is inquiring on a daily basis for clinical updates to keep SH’s in the loop. Goal is to get 50 patients injected as quickly as possible. They have filed for Basket trial to expedite enrollment.

They are in discussions with 18 companies for $40-$50M non dilutive financing. They expect non binding term sheets to begin hitting his desk next week.

Someone wanted to know about current $ in the bank. He was quite confident about the companies position with warrants being converted coupled with a much appreciated SP. He isn’t going to jump at any cash deals that take advantage of our current SP. I got the feeling Nader is very comfortable with the leverage that is starting to build with the BLA submission and mTNBC play.

NASH will have published data very soon and they feel there is a strong likelihood of a BP deal.

Number one I goal is to help the many patients lives that can be saved. Number two is SH’s ROI. He said we can’t reach goal number one without first achieving goal #2.

Things are ramping up on a daily basis in terms of possible PR’s. Once again why anyone in there right mind would sell this stock at this juncture is beyond me.

GLTAL’s

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News